Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
GD8-H5243 | Human | Human latent GDF-8 Protein, His Tag (MALS verified) |
|
|
Human Follistatin Protein, His Tag, premium grade (Cat. No. FON-H52H4) immobilized on CM5 Chip can bind Human latent GDF-8, His Tag (Cat. No. GD8-H5243) with an affinity constant of 364 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
The purity of Human latent GDF-8, His Tag (Cat. No. GD8-H5243) is more than 90% and the molecular weight of this protein is around 80-95 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Talditercept alfa | RO-7239361; BMS-986089; RG-6206; BHV-2000 | Phase 3 Clinical | Bristol-Myers Squibb Company | Muscular Dystrophy, Duchenne; Neuromuscular Diseases; Muscular Atrophy, Spinal | Details |
Apitegromab | SRK-015 | Phase 3 Clinical | Scholar Rock | Spinal Muscular Atrophies of Childhood; Neuromuscular Manifestations; Muscular Atrophy; Neuromuscular Diseases; Muscular Atrophy, Spinal; Atrophy | Details |
RO-7204239 | GYM-329; RO-7204239; RG-6237; RG-70240 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd | Muscular Dystrophy, Facioscapulohumeral; Muscular Atrophy, Spinal | Details |
Trevogrumab | REGN-1033; REGN1033; SAR-391786; GDF8 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Myositis, Inclusion Body; Obesity; Sarcopenia | Details |
AAV1-FS344 | AAV1-Follistatin; AAV1-FS344 | Phase 2 Clinical | Nationwide Children'S Hospital | Becker muscular dystrophy; Myositis, Inclusion Body; Muscular Dystrophy, Duchenne | Details |
ACE-2494 | ACE-2494 | Phase 1 Clinical | Acceleron Pharma Inc | Details | |
KER-065 | KER-065; RKER-065 | Phase 1 Clinical | Keros Therapeutics Inc | Neuromuscular Diseases; Obesity | Details |
This web search service is supported by Google Inc.